Zemdri carries a Boxed Warning describing reports of nephrotoxicity, ototoxicity, and neuromuscular blockade, as well as fetal harm if administered during pregnancy.
In the AWARD-7 trial, patients who received Trulicity 0.75mg or 1.5mg in combination with mealtime insulin lispro achieved similar glycemic control with weight loss vs patients who received traditional basal-bolus insulin.
A clinical trial assessing canagliflozin (Invokana; Janssen) as an addition to standard-of-care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) has been stopped early after meeting its pre-specified efficacy criteria.
In AWARD-7, eligible patients (N=577) were randomized to receive dulaglutide 1.5mg once-weekly (N=193), dulaglutide 0.75mg (N=190) once-weekly, or insulin glargine daily (N=194), all in combination with insulin lispro, for 52 weeks. HbA1c at 26 weeks with a 0.4% non-inferiority margin was designated as the primary outcome, while secondary outcomes included eGFR and urine albumin-to-creatinine ratio.
According to the authors, this is the first study to identify medications most commonly reported for a specific adverse reaction using this database.
After 12 weeks, 59.2% of patients treated with the study drug saw an increased blood bicarbonate of ≥4mEq/L or achieved a level in the normal range (22 to 29mEq/L) vs 22.5% of patients in the placebo group (primary endpoint; P <.0001).
Intradialytic hypotension is a common complication of hemodialysis and can lead to increased morbidity and mortality among patients with end-stage renal disease.
Crysvita, a recombinant fully human monoclonal IgG1 antibody, works by blocking fibroblast growth factor 23 (FGF23), a hormone that causes phosphate urinary excretion and suppresses vitamin D production by the kidney.
The efficacy of tolvaptan was demonstrated in two pivotal trials, lasting one year and three years, respectively.
Results showed that compared to metoprolol, those who initiated carvedilol had a greater all-cause (HR, 1.08; 95% CI,1.02-1.16) and cardiovascular mortality (HR, 1.18; 95% CI, 1.08-1.29).
Crysvita is an antibody that blocks fibroblast growth factor 23 (FGF23), a hormone that causes phosphate urinary excretion and suppresses active vitamin D production by the kidney.
Compared with the enalapril-treated group, those treated with sacubitril/valsartan were found to have significantly slower kidney decline (-1.3 vs -1.8mL/min/1.73m2 per year; P<0.0001).
The renal protective benefit was seen in patients with both reduced (eGFR <60mL/min/1.73m2) and preserved (eGFR ≥60mL/min/1.73m2) renal function.
The composite significant kidney event end point was defined as the first occurrence of ≥30% decline in eGFR to an eGFR <60mL/min/1.73m2, initiation of dialysis or kidney transplant.
Farxiga is a sodium-glucose co-transporter 2 (SGLT2) inhibitor currently indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2D mellitus.
For the report, AKI was defined as the occurrence of at least 1 diagnostic code 584 (acute renal failure) or the occurrence of at least 1 procedure code of 39.95 (hemodialysis) or 54.98 (peritoneal dialysis).
Regional variation in cumulative risk of an individual having a chest or abdominal CT in the United States was positively correlated with the risk of both total and partial nephrectomy, as well as any renal procedure (including renal ablation).
Outcomes after left ventricular assist device implantation significantly worse for those with end-stage renal disease
Patients with end-stage renal disease (ESRD) have significantly worse survival outcomes following left ventricular assist device (LVAD) implantation compared to recipients without ESRD.
Lixivaptan is a potent, selective vasopressin V2 receptor antagonist which has been found to delay the progression of an autosomal dominant form of polycystic kidney disease.
Patients with C3G experience progressive deterioration in renal function, ultimately leading to renal failure requiring dialysis and kidney transplant, if left untreated.